American Journal of
Biomedical Science & Research

www.biomedgrid.com
ISSN: 2642-1747

Review Article

Copyright © All rights are reserved by Loso Judijanto

Beyond Antioxidant Protection: Palm Oil-Derived Tocotrienols, Neurodegenerative Disease Mechanisms, and the Translational Gap between Experimental Models and Clinical Evidence

Loso Judijanto*

IPOSS Jakarta, Indonesia

***Corresponding author:** Loso Judijanto, IPOSS Jakarta, Indonesia

To Cite This article: *Loso Judijanto*, From Oil Palm Residues to Advanced Biomedical Materials: A Review of Nanocellulose Scaffolds, Controlled Drug Delivery, Wound Dressings, and Antimicrobial Engineering. Am J Biomed Sci & Res. 2026 32(5) AJBSR.MS.ID.004202,*

DOI: 10.34297/AJBSR.2026.32.004202

Received: October 23, 2026 **Published:** November 06, 2026

Abstract

Palm oil-derived tocotrienols have attracted attention as multifunctional neuroprotective candidates because their unsaturated vitamin E structures are associated with redox regulation, modulation of neuroinflammation, and effects on neuronal survival. Yet activity in experimental systems cannot establish clinical efficacy, particularly when products, congeners, models, and outcome measures differ. This qualitative literature review critically synthesises journal evidence published from 2020 to October 2026 across Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and neurovascular conditions. The synthesis organises findings around pharmacology, oxidative injury, microglial signaling, protein pathology, disease-model outcomes, delivery limitations, and human studies. Laboratory investigations reveal plausible effects on inflammatory mediators, tau phosphorylation, dopaminergic neuronal injury, and selected measures of cognition, however, much of this evidence remains model-specific. Human evidence is sparse and heterogeneous. Crucially, a 2026 placebo-controlled trial of a tocotrienol-rich vitamin E complex in CADASIL did not demonstrate reduced clinical progression over 24 months, despite acceptable tolerability. A smaller randomized cognitive study used rice-derived, not palm-derived, tocotrienols and therefore offers limited direct evidence for palm preparations. The review argues that successful translation requires chemical standardization, reproducible central exposure, target-engagement biomarkers, disease-stage selection, and adequately powered trials with clinically relevant endpoints. Current findings justify further hypothesis-driven investigation but not claims of established neurodegenerative disease modification.

Keywords: Palm oil, Tocotrienols, Neuroprotection, Neurodegeneration, Alzheimer's disease, Parkinson's disease, Neuroinflammation, Ferroptosis, Cerebral small vessel disease, Clinical translation

JEL Classification: I10 (Health: General), I12 (Health Behaviour), I18 (Government Policy, Regulation, Public Health), O32 (Management of Technological Innovation and R&D), Q16 (R&D and Agricultural Technology).

Introduction

Neurological Disease Burden, Treatment Limitations and the Search for Protection

Neurological disorders create a large and heterogeneous burden of disability, premature death and long-term dependence. The Global Burden of Disease analysis covering conditions of the nervous system estimated that 3.40 billion people were affected in 2021, although this umbrella category includes many conditions beyond the neurodegenerative diseases examined here. Alzheimer's disease, Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS) differ markedly in their pathology, rates of progression and established treatment options, but they frequently share oxidative injury, inflammatory amplification, mitochondrial abnormalities and impaired protein quality control. These shared features motivate interest in interventions able to influence more than one

This work is licensed under Creative Commons Attribution 4.0 License

molecular target, while also creating a risk of collapsing biologically distinct conditions into a single therapeutic narrative. A convincing evaluation must distinguish common cellular stress pathways from the disease-defining pathology that a treatment would actually need to alter [2,7,13,15]. The therapeutic landscape illustrates why mechanistic plausibility alone is insufficient. Disease-modifying anti-amyloid antibodies have demonstrated measurable effects on selected clinical outcomes in patients with biomarker-confirmed early Alzheimer's disease, yet they also require substantial safety monitoring and do not reverse established dementia. ALS research has produced genotype-specific approaches such as antisense therapy for SOD1-associated disease, underscoring the value of matching an intervention to a biologically defined population rather than treating a broad symptom category. In dementia prevention, longitudinal risk management, education, physical health and social factors remain central, and micronutrient interventions should not displace these proven or guideline-supported domains. The practical question is therefore not whether tocotrienols exhibit attractive laboratory signals, but whether those signals can be converted into a reproducible, safe and clinically meaningful effect in a specified population [32,33,38,48,52].

Palm-Derived Tocotrienols and the Distinction Between Promise and Proof

Tocotrienols are members of the vitamin E family that share a chromanol head group with tocopherols but possess an unsaturated isoprenoid side chain. The α, β, γ and δ congeners differ in methyl substitution, and such distinctions can influence membrane interactions, metabolism and signaling effects. Palm oil is a major commercial source of tocotrienol-rich material, although formulations vary in congener ratios and often contain tocopherols and other lipid constituents. It is scientifically inaccurate to treat all vitamin E compounds, all tocotrienol congeners or all commercial tocotrienol-rich fractions as interchangeable. A result for a purified α-tocotrienol preparation cannot automatically be generalized to a mixed palm extract, similarly, an investigation of rice- or annatto-derived tocotrienols is relevant pharmacological context but not direct proof for a palm-derived product [6,30,34,44]. Recent studies have accelerated attention to both the opportunities and limits of this field. Palm-derived δ-tocotrienol shows measurable uptake and anti-inflammatory activity in microglial systems, selected experimental Parkinsonian models show improvements in motor and histological outcomes after tocotrienol supplementation, and α-tocotrienol has been linked to inhibition of oxidative-stress-associated tau phosphorylation in cultured neuronal cells. Those findings concern different experimental platforms and do not jointly demonstrate disease modification in people. A prominent 2026 randomized trial in genetically confirmed CADASIL patients found no benefit on its composite clinical endpoint over 24 months. Because this result challenges a simple progression from antioxidant rationale to clinical neuroprotection, it is incorporated as a central finding rather than treated as an inconvenient exception [8,28,31,51].

Aim, Novelty and Boundaries of Inference

This review addresses seven linked questions: what pathways tocotrienols influence, where disease-model evidence is strongest, how congeners and mixtures differ, what pharmacokinetics implies for effective brain exposure, what human trials demonstrate, why translation may fail, and how future research should be designed. Its contribution is an evidence-calibrated map from compound identity to biological activity, disease-context relevance, clinical endpoints and decisions about further development. Related scoping reviews are valuable foundations, but the present review deliberately uses an interpretive qualitative approach rather than a new systematic count or pooled effect estimate. The emphasis is on explaining contradictions and the inferential steps between cellular activity and disease-specific human benefit. In particular, negative clinical evidence and product-source differences are treated as sources of knowledge rather than as reasons to abandon or exaggerate the underlying mechanisms [3,36,56].

Literature Review

Chemistry, Tissue Handling and Exposure as Prerequisites for Biological Effects

The protective functions attributed to vitamin E are often introduced through the prevention of lipid oxidation, but current pharmacology suggests a wider picture. Tocotrienol congeners may modify intracellular signalling, membrane behaviour and inflammatory mediators, while α-tocopherol remains the major circulating vitamin E form under ordinary conditions because vitamin E metabolism and transport are strongly isoform selective. Claims that tocotrienols are uniformly superior antioxidants can therefore mislead: potency depends on assay conditions, concentrations, membrane environments and the outcome being measured. Nutritional adequacy, pharmacological supplementation and experimental micromolar exposure are distinct exposure states. The most relevant translational metric is not the administered capsule mass but the unbound and biologically active concentration reaching the relevant neural, vascular or immune compartment over time [6,30,42]. Oral absorption represents a major limiting step. Tocotrienols are lipophilic, their uptake is influenced by food and formulation, and their systemic half-lives and relative congener distributions differ. Reviews comparing palm and annatto preparations describe differences in pharmacokinetic profiles, while self-emulsifying delivery systems seek to improve solubility and absorption consistency. Nanoencapsulation experiments in rats provide a particularly informative illustration: altering the vehicle changed plasma exposure and selectively enriched some congeners in brain and liver tissue. These outcomes are important for formulation research but do not establish that a specific delivery method yields functional neuroprotection or that rodent brain enrichment predicts human central nervous system exposure. Product quality studies should report the absolute amount of each tocotrienol, residual tocopherols, oxidative stability, excipients and batch-to-batch variation rather than relying solely on a branded 'tocotrienol-rich' description [14,39,42,46].

Oxidative Injury, Mitochondrial Integrity and Ferroptosis

Neurons consume substantial energy, maintain extensive membranes and depend on precisely regulated intracellular calcium and synaptic signaling. When mitochondrial function deteriorates, reactive oxygen species and lipid peroxidation products can accumulate, damaging membranes and reinforcing inflammatory stress. These processes occur alongside disease-specific triggers rather than acting as a complete explanation for neurodegeneration. Ferroptosis is a regulated form of death linked to iron-dependent phospholipid peroxidation and antioxidant defense systems, including glutathione-associated pathways. It offers a mechanistic bridge between membrane-protective compounds and degeneration, but demonstrating reduced oxidative markers is not equivalent to proving that ferroptosis was inhibited. Mechanistic attribution normally requires pathway-sensitive experiments, appropriate inhibitors and evidence that cell fate changes specifically through the proposed checkpoint [9,23,24,43,55]. The relevance of this framework to tocotrienols is theoretically substantial but experimentally uneven. Their membrane-associated chemistry provides a plausible capacity to alter lipid oxidative reactions, and cellular studies have suggested interactions with enzymes and stress-responsive signaling networks. Yet the causal chain—oral administration, adequate brain exposure, target engagement, lower pathological lipid peroxidation, preserved neurons, and delayed functional decline—has seldom been demonstrated in full within one model, much less in a trial. The distinction matters especially for chronic neurodegenerative disease, where altered lipid peroxidation might be downstream of pathological protein deposition or inflammatory injury. An intervention that reduces a downstream stress signal could improve a short-term biomarker without changing the trajectory of the defining disorder. Robust research should interrogate both mediator and endpoint, preferably with time-resolved measurements and blinded quantification [9,23,26,55,56]. Recent work places the Nrf2 network at the intersection of iron handling, glutathione homeostasis and the cellular susceptibility to ferroptosis. Nevertheless, the existence of an Nrf2–ferroptosis connection in neurodegenerative disorders should not be misconstrued as proof that orally administered tocotrienols inhibit ferroptosis in the human brain. Future experiments would be more informative if they assessed phospholipid oxidation products, GPX4-related defenses, iron metabolism and cellular rescue together, ideally with pathway-specific perturbation and measured concentrations of individual tocotrienol congeners [9,24,55].

Neuroinflammation, Microglia and Non-Neuronal Targets

Microglia and astrocytes participate in synaptic maintenance, tissue repair, immune surveillance and the removal of damaged cellular material. In disease, persistent or dysregulated inflammatory activation can amplify neuronal injury, but blanket suppression of microglia is neither always desirable nor likely to be a satisfactory long-term therapeutic objective. Contemporary reviews emphasize context-dependent glial states, reciprocal signaling with neurons, and interactions with vascular and peripheral immune compartments. NF-κB and Nrf2 pathways are frequently used as mechanistic organizing concepts because they connect inflammatory gene expression to oxidative stress responses. However, their activity varies by disease stage, cell type, stimulus and sampling time. Consequently, an observed reduction in one cytokine should be interpreted as modulation of a response under defined conditions, not evidence that the entire inflammatory cascade has been corrected [18,29,53]. An illustrative palm-specific study exposed BV2 cells and primary microglia to δ-tocotrienol and documented uptake alongside changes in nitric oxide, inducible nitric oxide synthase, prostaglandin E2 and selected cytokine-related outputs. Its controlled cellular observations support a pharmacodynamic effect on stimulated microglia, although differential effects across mediators also show that the response is not a universal shutdown of inflammation. More recently, a 2026 study of tocotrienol-rich fraction reported reductions in reactive oxygen and nitrogen-related responses in activated BV2 cells, accompanied by exploratory behavioral and gene-expression observations in rats. These findings are consistent with a multi-pathway hypothesis, but the pilot nature of the animal component, differences in preparations and uncertain human CNS exposure warrant cautious interpretation. Together they support prioritization of glial target-engagement experiments rather than routine clinical supplementation as neurodegenerative therapy [5,50,51].

Disease-Defining Biology and Why One Model Cannot Represent All Diseases

Alzheimer's disease is increasingly classified through biomarker evidence of amyloid and tau pathology, with clinical signs reflecting interactions among lesions, copathology, resilience and cognitive reserve. Neuroinflammation and vascular injury may modify progression, but reducing an inflammatory marker does not demonstrate clearance of amyloid or prevention of tau accumulation. Parkinson's disease is associated with pathological α-synuclein and a heterogeneous distribution of motor and non-motor manifestations, recent biological research frameworks seek greater consistency in identifying relevant patient subgroups. ALS involves highly heterogeneous genetic and cellular mechanisms affecting upper and lower motor neurons, glia and neuromuscular systems. These differences require separate models, biomarkers and endpoints. It is not appropriate to transfer a motor-score improvement from a toxin-based Parkinsonian rat experiment to expectations for cognition in Alzheimer's disease or survival in ALS [16,20,21,22,49]. Disease models also contain selective vulnerabilities. A toxin-challenged dopaminergic system can create relatively abrupt oxidative injury, whereas most people with Parkinson's disease develop pathology over many years. Transgenic amyloid models may reproduce plaque-related processes without capturing the full constellation of late-life human neuropathology. Cultured neuronal cell lines simplify interaction networks and may lack normal drug transport, aging-related changes and cerebrovascular features. Human neural organoids and biomarker-characterised cohorts may narrow certain gaps, but each platform has its own limitations. A serious translational program must therefore use complementarity rather

than substitution: experiments establish plausibility, animal models test functional integration, and appropriately selected human cohorts test whether a clinically meaningful process can be modified [7,16,26,40].

Method: Qualitative Literature Review

Interpretive Design and Source Boundaries

The review adopted a Qualitative Literature Review (QLR) design based on critical, interpretive and thematic synthesis. Its purpose was not to identify every publication or estimate a pooled intervention effect. Instead, selected publications were read in relation to the scientific questions they could reasonably answer: chemical identity, cellular action, animal function, pharmacokinetics, human efficacy or methodological context. Scholarly literature published between January 2020 and 22 October 2026 formed the evidential window. Topic clusters included "palm tocotrienol," "tocotrienol-rich fraction," individual tocotrienol congeners, neuroprotection, microglia, Alzheimer, Parkinson, ALS, CADASIL, cerebral small vessel disease, pharmacokinetics and brain delivery. Articles originating from peer-reviewed journals were prioritized, with direct clinical and experimental reports interpreted alongside disease biology and methodological reviews. This was a narrative selection process, not a PRISMA-guided systematic search. The distinction between direct and contextual evidence was integral to the design. Direct evidence involved intervention with a tocotrienol preparation and measurement of a neural, neurovascular or cognitive outcome. A second category concerned formulation, bioavailability or general pharmacology without direct clinical neuroprotection. A third category consisted of independent studies that established disease mechanisms, biomarker frameworks or current treatment standards. The latter were not used to claim tocotrienol effectiveness. Similarly, work involving tocopherol or multinutrient combinations was retained only for contrast, potential confounding or clinical study design. Older, historically important studies were acknowledged as background where necessary, but no article published before 2020 was included in the manuscript's reference list. This rule favors currency while making the synthesis explicit about the limited number of new palm-specific human outcome investigations.

Thematic Interpretation, Internal Checks and Limitations

The evidence was coded across six thematic domains: (i) tocotrienol composition and exposure, (ii) redox and ferroptosis-related mechanisms, (iii) glial and inflammatory pathways, (iv) disease-specific cellular and animal outcomes, (v) human clinical and imaging outcomes, and (vi) translational design requirements. Each claim was classified qualitatively according to its inferential position: mechanistic observation, animal functional association, observational human association, controlled human endpoint or research proposal. Where papers reported mixed or negative outcomes, these were preserved rather than averaged into a broad positive conclusion. Particular attention was paid to whether a study measured actual brain exposure, target engagement, histopathology, validated clinical function, or merely a surrogate signal. This analytic distinction helps readers separate biochemical plausibility from treatment efficacy without pretending that a narrative review can replace formal risk-of-bias assessment. The QLR approach supports conceptual integration but entails selection and interpretation risks. It cannot provide a reproducible completeness estimate, formal meta-analysis, certainty rating or universal quantitative hierarchy of effect sizes. Publication bias may favor positive animal results, while reviews can repeat claims based on overlapping original studies. Some contemporary papers have commercial or institutional relationships related to vitamin E products, and clinical trial sponsorship may influence the importance of transparent protocols and prespecified analyses. The review consequently emphasizes independent replication, preregistration, blinded outcomes and the distinction between primary and exploratory endpoints. No conclusion is based on a simple vote count of positive and negative studies, instead, the clinical implications follow the design and relevance of the strongest available evidence. The final interpretation is conditional on the evidence published by the stated cutoff date.

Results: Thematic Findings

Cross-Cutting Biochemical and Inflammatory Signals

Across the direct experimental literature, the most reproducible theme is modulation of stress-associated responses rather than established prevention of chronic neurodegenerative disease. Palm-derived δ-tocotrienol is taken up by activated microglial cells and is associated with lower nitric oxide and selected eicosanoid responses. A separate 2026 tocotrienol-rich fraction experiment identified changes in oxidant-related measures, inflammatory transcripts and factors involved in cellular resilience, however, its in vivo pilot component does not establish long-term disease modification. Broader reviews describe plausible actions involving NF-κB-associated inflammation, oxidative stress, membrane protection and neurotrophic signaling. These findings are compatible with each other at a conceptual level, but protocols, concentrations and tissue targets are too different to justify a single pooled efficacy statement. Critically, an inflammatory response in a stimulated cell line is an assay phenotype, not itself a clinical syndrome [5,50,51,56]. An important limitation lies in the interpretation of pathway names. When Nrf2-associated transcripts rise or NF-κB-associated targets fall, authors may infer enhanced antioxidant defense or lower inflammation, but direct transcription-factor activation, protein localization, pathway inhibition and functional rescue are separate measurements. Likewise, anti-oxidative capacity measured in a cell-free assay may not predict intracellular protection under physiological oxygen tension. In ageing tissue, oxidative injury, innate immune activation, synaptic degradation and vascular insufficiency can reinforce one another through feedback loops, making a single-marker change difficult to assign to one upstream cause. The literature therefore supports a network model of potential influence rather than a proven linear mechanism. More persuasive experiments would combine congener-resolved tissue pharmacokinetics with causal pathway perturbation and outcomes that matter at the tissue or organism level [18,24,36,53,55].

Comparison of the experimental reports further reveals a recurring challenge of assay comparability. Some experiments isolate a single tocotrienol congener and apply it directly to immortalised or primary cells, whereas others administer a mixed fraction through a nutritional vehicle to an intact animal. The resulting biological readouts are not interchangeable. A change in nitric oxide production, for instance, may reflect altered inflammatory signalling at a defined stimulus intensity without establishing protection against sustained neuronal injury. Likewise, improvements in a Parkinsonian motor task can be influenced by lesion severity, dosing interval and testing methodology. A stronger synthesis therefore asks whether effects are robust to dose-ranging experiments, blinded assessments, vehicle-matched controls and replication in a biologically complementary model. These distinctions are essential when the source material is variably labelled as palm-derived extract, purified tocotrienol or mixed vitamin E fraction [28,31,51,56]. The translational relevance of a favorable molecular signal also depends on temporal order. If tocotrienol is delivered before oxidative or toxin injury, the experiment primarily addresses prophylactic resilience, administration after established damage tests a different and often more clinically relevant therapeutic question. These schedules cannot simply be pooled into a general neuroprotection narrative. Moreover, measured antioxidant responses do not identify which upstream disease process has been modified unless investigators simultaneously quantify disease-relevant pathology and viable tissue. This is particularly important in slow-progressing neurodegenerative conditions, in which synaptic dysfunction, glial state changes and neuronal death may develop on different timescales. Future studies should explicitly register dosing windows, characterize exposure to individual congeners, state the hypothesized cellular target and link proximal pharmacodynamic changes to durable functional measures [24,26,27,50].

Figure 1 maps the proposed molecular routes between a chemically specified tocotrienol exposure and downstream outcomes. It is intentionally drawn as a conceptual synthesis rather than a claim that all the pathways have been validated in a single study. The placement of exposure and clinical endpoints in the same diagram highlights how many inferential steps remain between reducing cell stress and preventing disability. The diagram also clarifies why formulation belongs within the biological argument: insufficient brain exposure can break the causal sequence before even a highly plausible molecular mechanism is tested (Figure 1).




Figure 1: Proposed pathway architecture from palm-derived tocotrienols to neuroprotective outcomes.

Source: Original qualitative synthesis of the cited literature. Arrows indicate candidate biological and translational relationships; none should be interpreted as established clinical causality.

Alzheimer's Disease: Tau Regulation, Glial Activity and Unresolved Disease Modification

Alzheimer's disease provides an attractive theoretical target for a compound that influences lipid damage, immune signalling and neuronal stress. Its underlying pathology, however, is much more specific than general oxidative injury: amyloid-related pathology, tau changes, synaptic dysfunction, vascular interactions and inflammatory effects evolve over long intervals and vary among individuals. Biomarker frameworks have increasingly separated the biological presence of Alzheimer's disease from clinical staging, reinforcing the need to enroll relevant populations in intervention studies. Laboratory investigation of α-tocotrienol found reduced oxidative-stress-related tau phosphorylation at Ser262 in a neuronal cell line, potentially associated with lower microtubule affinity-regulating kinase activation. This supports a targeted signaling

hypothesis but does not demonstrate prevention of human neurofibrillary pathology, amyloid plaque progression or loss of independence [21,22,26,31]. Broader interpretations of vitamin E and cognition require careful disaggregation. A 2025 scoping review collated heterogeneous tocotrienol-rich fraction investigations and described multiple cellular, animal and cognition-related signals. A separate scoping review contrasting tocotrienols with tocopherols identified variation in measured vitamin E isoforms and human brain-related outcomes. These reviews make the literature more navigable but do not convert their included experimental studies into clinical evidence. Associations between tocopherol concentrations and lower activated microglial density in elderly human cortex, for example, concern another vitamin E class and are observational rather than causal. Similarly, a multicomponent supplement containing carotenoids, omega-3 fatty acids and vitamin E does not isolate the role of palm tocotrienols. Consequently, results for the vitamin E family should contextualize, but never substitute for, direct intervention studies with chemically specified tocotrienols [5,10,41,44]. Recent dementia intervention studies provide an appropriate standard of clinical interpretation. The donanemab and lecanemab trials recruited participants with early symptomatic Alzheimer's disease and biological evidence of relevant pathology, and measured longitudinal clinical outcomes alongside laboratory or imaging information. They were not tocotrienol trials and should not be used as indirect support for tocotrienol treatment, but their designs illustrate the demanding evidentiary conditions for any disease-modifying claim. Microglial activation and abnormal protein propagation are themselves heterogeneous, as suggested by work on microglial involvement in amyloid spread. A future tocotrienol trial could therefore use validated amyloid, tau or injury biomarkers for population selection and exploratory biological evaluation, while retaining prespecified cognitive or functional endpoints as the ultimate test of clinical relevance [12,29,3748,52].

Parkinson's Disease: Encouraging Experimental Phenotype, Limited Clinical Bridge

The strongest direct disease-model signal identified here concerns toxin-induced parkinsonism. In a 6-hydroxydopamine rat study, α- and γ-tocotrienol treatment after lesion induction was associated with improvements in motor measures and preservation of dopaminergic neuronal markers and striatal fibers. Such a combination of behavior and histology is more persuasive than an isolated antioxidant assay because it spans several levels of biological function. Nevertheless, 6-hydroxydopamine produces a chemically induced lesion, and its time course does not recapitulate all features of idiopathic Parkinson's disease, especially distributed α-synuclein pathology, prodromal change and long-term multisystem decline. The observations justify replication with exposure controls and complementary models, but they are not a clinical estimate of reduced progression in people with Parkinson's disease [7,28,40]. Contemporary Parkinson's disease research has moved toward molecular classification and biomarker-grounded subgroups. Proposed approaches based on neuronal α-synuclein, evidence of neurodegeneration and genetics suggest ways to reduce patient heterogeneity in experimental trials, although several classifications are research frameworks rather than routine clinical diagnostic directives. Seed amplification studies have also demonstrated that biologically defined Parkinsonian cohorts can differ from symptom-based groupings. For tocotrienol development, these advances imply that early trials should define whether the intended outcome is symptomatic motor improvement, altered inflammatory status, slowing dopaminergic loss or reduction in a validated marker of disease pathology. Without such a distinction, an improvement in a motor task could reflect many processes unrelated to genuine neuroprotection. This uncertainty is a research-design challenge, not a reason to deny the preclinical result [20,28,47,49].

ALS, Retinal Neurodegeneration and Other Disease Boundaries

Compared with the Parkinsonian literature, direct post-2020 evidence that palm-derived tocotrienols preserve motor neurons or alter ALS progression is particularly limited. ALS involves combinations of altered RNA processing, protein homeostasis, axonal transport, glial activation, metabolic dysfunction and genotype-specific biology. Some of these processes overlap conceptually with tocotrienol targets, but a mechanistic match is not evidence of efficacy. Translation to ALS would first require experiments in appropriately chosen disease-relevant motor-neuron systems, with electrophysiology and long-term neuronal survival measures, followed by multi-model replication. The existing genotype-specific clinical research landscape shows why precision matters: a response in one molecular subgroup need not generalize to other ALS populations. At present, the responsible characterization of tocotrienols in ALS is an exploratory mechanistic hypothesis, not a validated therapeutic strategy [13,16,17,38]. A separate 2020 investigation used palm-derived tocotrienol-rich fraction in rats with diabetic retinopathy and found protective effects on aspects of retinal neurodegenerative change. Retinal neurons and glia offer a useful biological setting for studying oxidative, vascular and inflammatory injury, and the retina may permit quantifiable structural and functional observation. However, diabetic retinal injury is not interchangeable with Alzheimer's disease, Parkinson's disease or ALS, and improvement in retinal endpoints cannot substitute for brain-specific outcomes. The relevance of such evidence is to show that a palm preparation may act in neural tissue under some conditions, while encouraging investigation of shared microvascular and neuronal stress features. Its limitations also reinforce the need to state exactly what disease process a given experimental result model. Careful nomenclature helps prevent inappropriate aggregation under the broad label of 'neurodegeneration' [26,45,54].

Human Cognitive Data and the Decisive CADASIL Signal

Clinical evidence is thinner than the mechanistic literature and includes important source distinctions. In a 2025 placebo-controlled trial of 91 adults with subjective memory complaints, a 100 mg daily preparation of rice-derived tocotrienols was studied over 12 weeks. Greater improvement was reported in selected memory indices, while other cognitive measures did not show between-group

differences, and changes in inflammatory markers were not uniformly favorable. Because this was a short-duration study in participants without a confirmed neurodegenerative diagnosis and used a rice-derived product, it cannot substantiate disease modification by palm-derived tocotrienols. The study remains useful for hypothesis generation about human cognition, tolerability and endpoint selection. A separate 2025 protocol proposed investigation of a tocotrienol-rich fraction in older adults, but a protocol is not evidence that the planned outcomes have been achieved [3,4,35]. The 2026 T3CAD study provides the most direct recent test of palm-derived tocotrienol-rich vitamin E against clinically meaningful progression in a defined human neurological disorder. Fifty-one genetically confirmed CADASIL patients were randomized to HOV12020 or placebo over 24 months, treatment failure combined stroke occurrence, progression of disability and cognitive deterioration. Treatment failure occurred in 68.0% of the active-treatment group and 61.5% of placebo recipients, and the Bayesian analysis met prespecified futility criteria. Secondary clinical outcomes and exploratory MRI measurements did not reveal significant treatment benefit. The intervention was well tolerated without a clear safety excess, an important but distinct observation. This trial therefore supplies evidence against clinical efficacy of that preparation, in that setting and disease stage, it does not establish that every congener, dosage or earlier disease stage is ineffective, nor does it permit claims of effectiveness based on preclinical precedent [8,11]. Contemporary work on vascular cognitive impairment identifies several candidate fluid and imaging markers, but none can be assumed to establish efficacy simply because it changes after treatment. Circulating neurofilament light chain is a useful indicator of neuro-axonal injury across neurological disorders, although ageing, comorbidity, disease context and assay characteristics complicate interpretation. Accordingly, a future tocotrienol trial should define whether its biomarker is intended to establish target engagement, downstream tissue protection or prognosis, and must not substitute a nonspecific marker for functional benefit [19,27].

Interpretation of the CADASIL finding requires attention to both internal validity and external limits. CADASIL is a genetic cerebral small vessel disease in which white matter abnormalities, lacunes and progressive functional effects can be quantified, making it a strategically informative but relatively specific population. Imaging standards have advanced considerably and reinforce the importance of consistent acquisition and predefined markers. The 2026 trial identified disease progression in both groups, but measured no treatment-related difference in the evaluated endpoints, exploratory diffusion-related measures were available in only a subset. The negative finding should therefore be neither dismissed because the sample was modest nor overgeneralized to all neurodegenerative diseases. Rather, it shifts the burden of proof: future studies must explain why an alternative population, timing, exposure or formulation would plausibly achieve a benefit that this rigorous trial did not detect [8,11,19,37].

Figure 2 presents a qualitative map of evidentiary maturity by experimental and clinical tier. The longer bars for cellular and animal studies indicate a broader mechanistic evidence base, not a larger therapeutic effect, no effect-size meta-analysis has been performed. The graphic intentionally places the negative CADASIL efficacy test within the human evidence tier so that relative research abundance is not confused with proof of benefit. As the corpus evolves, such a matrix should be updated using prespecified evidence classifications rather than merely adding positive study counts (Figure 2).




Figure 2: Illustrative distribution of evidence across research tiers. Bar widths convey qualitative breadth of investigation rather than therapeutic benefit, study quality, comparative evidentiary certainty, or effect size.

Source: Original synthesis.

Discussion and Analysis

Interpreting Convergence without Exaggerating Causality

The studies reviewed converge on a plausible proposition: tocotrienols can influence redox-sensitive and immune-related neural responses under experimental conditions. This convergence is biologically coherent because inflammation, abnormal lipid handling, mitochondrial stress and synaptic loss interact across many neurological disorders. Yet cross-study thematic agreement is not equivalent to a treatment effect. The evidence includes different tocotrienol congeners, sources, cell types, disease triggers, species, study lengths and endpoints. A cultured microglial response, a toxin-lesion motor outcome and a null randomized trial do not become mutually confirming when described as 'neuroprotective'. Instead they address sequential but distinct claims. A useful vocabulary would reserve 'mechanistic activity' for molecular assays, 'preclinical protection' for demonstrated tissue or animal effects, and 'clinical benefit' only for adequately supported human outcomes [8,28,51,56]. The most important difference among these evidence classes is proximity to the clinical target. A favorable signal in a neuronal cell line demonstrates that compound and assay can interact, an animal with a defined lesion additionally tests absorption, distribution and integrated function, a human randomized study tests a formulation in a clinical population amid biological heterogeneity and competing influences. The CADASIL result raises the possibility that either target engagement was inadequate, the biological pathways were insufficient for the complex disease, the intervention came too late, or the experimental effect does not translate. Existing evidence does not determine which explanation is correct. Crucially, each alternative requires a different follow-up experiment. Higher dose without exposure measurement is not a scientific resolution, and earlier treatment without credible safety and efficacy rationale remains only a hypothesis [8,26,42].

Congener Identity and Product Source are Causal Variables, not Administrative Details

Too much of the public and scientific discussion treats tocotrienols as a uniform nutritional intervention. Structural isomers have distinct substitution patterns, selective tissue handling and potentially different signaling profiles. Products described as 'tocotrienol-rich fraction' can have varying ratios of α, γ and δ forms, while tocopherols, oil carriers and delivery systems can change the absorbed profile. Comparative studies of formulation and biodistribution suggest that the compound reaching brain tissue need not resemble the proportions administered orally. This means that nominal milligram dosage across trials is an imperfect comparator unless congener-specific pharmacokinetics and formulation features are reported. Similarly, palm-derived material and a rice-derived test product cannot be conflated without a bridging compositional and exposure study. Better reporting may explain some apparent contradictions and increase the reproducibility of otherwise promising laboratory results [14,35,39,44,46]. The pharmaceutical relevance of these variables is substantial. A viable neuroprotective intervention requires formulation stability during storage, predictable absorption, suitable systemic tolerability, sufficient central exposure and a therapeutic margin across the planned population. Blood–brain barrier physiology creates another constraint: lipophilicity alone does not guarantee useful concentrations in the right brain compartment, particularly when protein binding, transporters, lipid trafficking and rapid elimination are considered. Nanoformulations and self-emulsifying systems offer credible technological approaches, but their benefits must be established using comparative pharmacokinetic and safety designs rather than assumed from particle size. In early trials, repeated concentration measurements and metabolite profiles may be more informative than increasing the number of loosely related oxidative biomarkers. A congener-resolved exposure model is a precondition for determining whether efficacy failure reflects inadequate delivery or an ineffective biological hypothesis [14,39,42,54].

Which Neurological Indication Merits the Next Trial?

For longitudinal studies, neurofilament light chain could be incorporated as an exploratory indicator of neuronal injury rather than as a stand-alone surrogate endpoint for tocotrienol efficacy. A contemporary review describes its increasing use in clinical monitoring across neurological conditions, while an Alzheimer-focused synthesis notes that it is not specific to Alzheimer pathology. This distinction reinforces a combined strategy involving disease-defining markers, exposure verification, prespecified clinical endpoints and sensitivity analyses for age-related confounding [25,27,37]. A rational prioritization approach begins with the strength of the entire evidence chain, not merely the severity of the unmet medical need. Parkinsonian toxin models offer an integrated behavioral–histological signal, yet the absence of definitive direct clinical Parkinson trials and the limited representation of α-synuclein biology are serious gaps. Alzheimer's disease provides tau-related mechanistic findings but lacks compelling modern palm-specific clinical efficacy data. ALS has a major scientific and ethical need, but the present palm-tocotrienol literature is too indirect to justify large efficacy trials before disease-relevant mechanistic work. Cerebral small vessel disease has the most instructive direct clinical test and a negative result in CADASIL, so the next study in that domain should probably prioritize explaining the null effect and determining exposure/target engagement rather than simply repeating an unmodified efficacy trial. These rankings reflect evidentiary readiness, not certainty that one disorder is inherently more responsive [8,13,28,31]. An appropriate proof-of-mechanism trial could recruit a narrowly defined population with demonstrable inflammatory or oxidative pathway involvement, employ a standardized preparation with prespecified brain-relevant exposure, and assess both pharmacodynamic markers and sensitive exploratory function over a suitable interval. Such a design differs from an effectiveness trial because its primary goal is to resolve whether the hypothesized mechanism operates in people at tolerable doses. Before disease-modification trials, investigators should determine the minimum clinically important difference, expected rate of change, available biomarker reliability, and sources of attrition. For Alzhei-

mer's disease, contemporary biological diagnostic criteria provide possible stratification principles, for Parkinson's disease, α-synuclein-based research frameworks offer other choices. However, neither classification framework makes tocotrienols disease-modifying without randomized endpoint evidence [20,21,22,27,37,49].

Potential comparisons should also be cautious about supplement combinations. The nutritional literature contains multivitamin and dietary studies that may link higher vitamin E exposure to cognitive outcomes, yet such designs cannot isolate a tocotrienol effect. When the intervention includes fatty acids, carotenoids or other antioxidants, any apparent benefit belongs to the tested combination, not automatically to its vitamin E component. If the purpose is to establish a drug-like neuroprotective claim, trials must use chemically characterized active material, an appropriate comparator, adherence measures, prespecified analyses, blinded endpoint assessment and clear registration. Commercial provenance and conflicts of interest should be disclosed prominently and independently replicated work prioritized. These safeguards make both positive and negative studies more interpretable and protect against selective emphasis on attractive subgroup findings [3,4,10,41].

Scientific, Manufacturing and Public-Health Implications

For manufacturers of palm-derived bioactives, the defensible pathway to value creation is rigorous standardization rather than broad neuroprotection marketing. Raw material provenance, extraction conditions, oxidation control and impurity profiles influence product reproducibility. Industrial quality systems should distinguish nutrients intended for general consumption from products being investigated for specific therapeutic indications. The latter require clinical development and regulatory evaluation proportionate to the intended claim. Traceability and responsible sourcing are relevant because a biomedical product built around a plantation supply chain should not disregard environmental or labor impacts. These concerns do not determine pharmacological efficacy, but they matter for ethical development, transparent supply relationships and social acceptance. A high-quality translational program would therefore coordinate analytical chemists, pharmacologists, neuroscientists, clinical trialists and sustainability specialists under an explicit evidence governance plan [34,42,46]. A public-health interpretation also needs proportionality. Dementia and other neurological conditions are influenced by a mixture of age, genetics, vascular health, socioeconomic context and cumulative exposures, current prevention strategies address a wide set of modifiable risks. No tocotrienol supplement should be described as replacing proven vascular risk management, appropriate neurological diagnosis or established therapies. Safety signals from selected trials are encouraging but do not settle questions about very long-term dosing, polypharmacy, interactions, frailty or differing formulations. Moreover, an apparently safe supplement can carry an opportunity cost if it creates misplaced confidence or delays evidence-based care. Translational maturity therefore includes communication quality: consumers and clinicians should be told which findings are cellular, which are experimental animal observations, and which are controlled human outcomes. That standard remains important even when the intended use is prevention rather than treatment [1,2,8,32].

Prioritized Research and Clinical-Development Roadmap




Figure 3: Six-stage, criteria-gated translational research roadmap, requiring exposure confirmation and target engagement before formal efficacy evaluation.

Source: Original synthesis.

Figure 3 organizes a staged research program with explicit go/no-go decisions. The first stage is analytical: establish stable, reproducible composition with congener-specific assays and independent testing of impurities. The second stage measures human exposure, food effects and dose proportionality, while concurrently addressing whether active metabolites or congeners plausibly reach neural tissue. The third stage establishes target engagement using pathway-specific readouts rather than a broad panel of weakly interpretable biomarkers. The fourth stage verifies disease relevance through complementary experimental models and validated biomarkers, ideally integrating human-derived cell systems. Only then should a small randomized proof-of-mechanism study test whether measured target engagement translates into a credible biological signal in a defined patient group. An adequately powered efficacy trial should follow only if these milestones and predefined futility boundaries are met [8,11,14,19,27,54]. A practical decision gate should stipulate in advance the minimum exposure achieved, assay repeatability, direction and magnitude of the intended pharmacodynamic response, and a threshold for unacceptable adverse events. For exploratory injury biomarkers, investigators should additionally control for clinically important covariates and establish analytical comparability between trial sites. These safeguards are particularly relevant where a biomarker signal might otherwise be overread as clinical disease modification [19,27] (Figure 3).

The figure also makes clear why trial design is part of the scientific mechanism. A nominally negative result may arise from inappropriate population choice, insufficient exposure or a truly ineffective biological concept, but an adequately designed study can limit these ambiguities. In genetically defined diseases, subgroup size and practical recruitment constraints may favor Bayesian approaches with prospectively specified futility criteria, as illustrated by T3CAD. In common conditions, larger cohorts may be needed to distinguish a modest disease effect from ordinary measurement variation and competing comorbidities. Investigators should prespecify primary endpoints, ensure centralized and blinded image analysis, use pharmacokinetic sampling that can establish adherence, and report negative results in full. Dose escalation or formulation changes should not be interpreted as evidence of rescue until an independent trial demonstrates their proposed effects [8,11,17,27]. Clinical research should additionally investigate whether the relevant mechanism is preventive, symptomatic or truly disease-modifying. A compound could plausibly improve sleep or subjective cognition without preventing amyloid, α-synuclein pathology, motor-neuron loss or small vessel injury. Conversely, an intervention might modify a biological marker while leaving function unchanged because the treatment began too late or the marker is not causally linked to disability. Separating these scenarios requires longitudinal designs and explicit mediation hypotheses. An intermediate trial may test exposure, pathway engagement and validated biomarkers simultaneously, but an eventual patient-centered outcome remains indispensable. This distinction reflects the modern direction of biological classification in neurodegeneration and protects the field against treating surrogate improvement as proof of clinical protection [21,35,38,48,49].

Strengths, Uncertainties and Directions for Interdisciplinary Research

The major strength of the present synthesis is its integration of chemical composition, cellular mechanisms, animal observations, exposure constraints and recent human trial data within a single interpretive framework. It resists the common tendency to present any vitamin E result as supporting every tocotrienol preparation and gives explicit attention to clinically neutral or negative findings. The approach also foregrounds the need for disease specificity: a compound that changes microglial signaling may be relevant to numerous diseases, but relevance alone does not determine clinical utility. The principal limitation is that a QLR cannot certify exhaustive study capture or provide pooled effect sizes, and the literature contains relatively few independent palm-specific clinical studies. Findings may also change with ongoing trials and improved biomarker science. Future reviews should be updated when new randomized endpoints are published and may then support focused systematic evaluation of a sufficiently homogeneous clinical question [3,8,44,56]. In practical terms, four research collaborations appear especially valuable. Analytical and formulation groups should create reference preparations characterized by congener, oxidation state and excipient profile. Experimental neuroscientists should map dose-dependent pathway changes in models that reproduce disease-defining pathology, including appropriate negative controls. Clinical pharmacologists should quantify interindividual variation, systemic exposure and any feasible central pharmacodynamic markers. Trial networks should then test a narrow indication using adjudicated endpoints and independent data oversight. A credible consortium could publish null results and assay specifications openly, reducing wasted replication and enabling better meta-research. The goal would not be to prove a preconceived claim about palm-derived compounds, but to determine under what conditions—if any—a reproducible patient benefit emerges. Such a strategy would make subsequent commercialization and public-health decisions more scientifically defensible [14,28,42,50,53].

Conclusion

Palm-derived tocotrienols possess credible experimental neurobiological activity, particularly in studies of oxidative responses, microglial signaling, neuronal stress and selected disease models. Their value as multifunctional research compounds arises from this breadth of potential actions, but those same multiple pathways can complicate causal interpretation. The distinction between a demonstrable laboratory response and a clinically relevant intervention remains fundamental. Current evidence supports continued scientific investigation of defined tocotrienol congeners and carefully characterized mixtures, it does not support a general conclusion that palm-derived tocotrienols prevent or slow Alzheimer's disease, Parkinson's disease, ALS or cerebral small vessel disease in humans. Emerging human data are heterogeneous. A short-term cognitive study with rice-derived tocotrienols provides a limited signal in a population without established neurodegenerative disease, whereas the rigorously designed CADASIL trial of a palm-derived tocotrienol-rich complex did not show clinical

or imaging benefit over two years despite acceptable tolerability. This contrast strengthens, rather than weakens, the case for disciplined translational research. Future studies must resolve formulation differences, measure relevant exposure, demonstrate target engagement, define biologically appropriate populations, and use prespecified functional outcomes that distinguish symptomatic change from disease modification. The priority recommendation is a gated translational program, not immediate large-scale efficacy claims. Product standardization, comparative pharmacokinetics, replicated disease-relevant experiments and biomarker-guided proof-of-mechanism trials should precede expensive efficacy investigations. Transparent reporting of null findings, conflicts of interest and sourcing practices is essential for scientific integrity and responsible innovation. If future trials establish meaningful clinical benefit in a clearly defined indication, palm-derived tocotrienols could become an important example of evidence-based biomedical value creation. Until then, their neuroprotective promise should be communicated as a testable research proposition rather than an established clinical fact.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Alzheimer's Association (2024) 2024 Alzheimer's disease facts and figures. Alzheimer's & Dementia 20(5): 3708–3821.
2. Alzheimer's Association (2026) 2026 Alzheimer's disease facts and figures. Alzheimer's & Dementia 22(4): e71345.
3. Amin AM, Mostafa H (2026) Vitamin E and cognitive function: A systematic review of clinical evidence. Nutr Res 145: 66–86.
4. Amir Razak, NAN Goon JA, Wan Ngah WZ, Suzana Makpol, Mohd Hanafi Ahmad Damanhuri, et al. (2025) Effectiveness of tocotrienol-rich fraction in older adults: Protocol for a randomized, double-blind, placebo-controlled trial. JMIR Research Protocols 14: e73039.
5. Ang SY, Bhuvanendran S, Lee VLL, Tan JY, Radhakrishnan AK, et al. (2025) Modulation of NF-κB signaling pathway by tocotrienol in neurodegenerative diseases. Discover Mental Health 5: 160.
6. Blaner WS, Shmarakov IO, Traber MG (2021) Vitamin A and vitamin E: Will the real antioxidant please stand up?. Annu Rev Nutr 41: 105–131.
7. Bloem BR, Okun MS, Klein C (2021) Parkinson's disease. The Lancet 397(10291): 2284–2303.
8. Chabriat H, Biard L, Guey S, Nassira Alili, Carla Machado, et al. (2026) Tocotrienol-rich vitamin E complex in CADASIL (T3CAD): a randomised, double-blind, placebo-controlled trial. EClinicalMedicine 94: 103853.
9. David S, Ryan F, Jhelum P, Kroner A (2023) Ferroptosis in neurological disease. The Neuroscientist 29(5): 591–615.
10. De Leeuw FA, Schneider JA, Agrawal S, Leurgans SE, Morris MC (2020) Brain tocopherol levels are associated with lower activated microglia density in elderly human cortex. Alzheimer's & Dementia: Translational Research & Clinical Interventions 6(1): e12021.
11. Duering M, Biessels GJ, Brodtmann A, Christopher Chen, Charlotte Cordonnier, et al. (2023) Neuroimaging standards for research into small vessel disease—advances since 2013. The Lancet Neurol 22(7): 602–618.
12. D'Errico P, Stephanie Ziegler Waldkirch, Vanessa Aires, Philippe Hoffmann, Charlotte Mezö, et al. (2022) Microglia contribute to the propagation of Aβ into unaffected brain tissue. Nature Neuroscience 25(1): 20–25.
13. Feldman EL, Goutman SA, Petri S, Letizia Mazzini, Masha G Savelieff, et al. (2022) Amyotrophic lateral sclerosis. The Lancet 400(10360): 1363–1380.
14. Fu JY, Meganathan P, Gunasegaran N, Tan DMY (2023) Effect of nano-delivery systems on the bioavailability and tissue biodistribution of vitamin E tocotrienols. Food Research International 171: 113048.
15. GBD 2021 Nervous System Disorders Collaborators (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology 23(4): 344–381.
16. Goutman SA, Hardiman O, Al Chalabi A, Adriano Chió, Masha G Savelieff, et al. (2022a) Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. The Lancet Neurology 21(5): 465–479.
17. Goutman SA, Hardiman O, Al Chalabi A, Adriano Chió, Masha G Savelieff, et al. (2022b) Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. The Lancet Neurology 21(5): 480–493.
18. Heneka MT, Van der Flier WM, Jessen F, Jeroen Hoozemanns, Dietmar Rudolf Thal, et al. (2025) Neuroinflammation in Alzheimer disease. Nature Reviews Immunology 25: 321–352.
19. Hosoki S, Hansra GK, Jayasena T, Anne Poljak, Karen A Mather, et al. (2023) Molecular biomarkers for vascular cognitive impairment and dementia. Nature Reviews Neurology 19: 737–753.
20. Höglinger GU, Adler CH, Berg D, Christine Klein, Tiago F Outeiro, et al. (2024) A biological classification of Parkinson's disease: The SynNeurGe research diagnostic criteria. The Lancet Neurology 23(2): 191–204.
21. Jack CR Jr, Andrews JS, Beach TG, Teresa Buracchio, Billy Dunn, et al. (2024a) Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia 20(8): 5143–5169.
22. Jack CR Jr, Andrews SJ, Beach TG, Teresa Buracchio, Billy Dunn, et al. (2024b) Revised criteria for the diagnosis and staging of Alzheimer's disease. Nature Medicine 30: 2121–2124.
23. Jakaria M, Belaidi AA, Bush AI, Ayton S (2021) Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease. Journal of Neurochemistry 159(5): 804–825.
24. Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22: 266–282.
25. Jung Y, Damoiseaux JS (2024) The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease. Brain 147(1): 12–25.
26. Kampmann M (2024) Molecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases. Nature Reviews Neuroscience 25: 351–371.
27. Khalil M, Teunissen CE, Lehmann S, Markus Otto, Fredrik Piehl, et al. (2024) Neurofilaments as biomarkers in neurological disorders-towards clinical application. Nature Reviews Neurology 20: 269–287.
28. Kumari M, Ramdas P, Radhakrishnan AK, Kutty MK, Haleagrahara N (2021) Tocotrienols ameliorate neurodegeneration and motor deficits in the 6-OHDA-induced rat model of parkinsonism: Behavioural and immunohistochemistry analysis. Nutrients 13(5): 1583.
29. Leng F, Edison P (2021) Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here?. Nat Rev Neurol 17(3): 157-172.
30. Liu Y, Fukui K (2026) Comparative neuroprotective and antioxidant roles

of vitamin E isoforms: A review. J Clin Biochem Nutr 79(2): 125-130.

31. Liu Y, Chen Y, Fukui K (2024) α-Tocotrienol protects neurons by preventing tau hyperphosphorylation via inhibiting microtubule affinity-regulating kinase activation. Int J Mol Sci 25(15): 8428.

32. Livingston G, Huntley J, Liu KY, Sergi G Costa freda, Geir Selbæk, et al. (2024) Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404(10452): 572-628.

33. Livingston G, Huntley J, Sommerlad A, David Ames, Clive Ballard, et al. (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396(10248): 413-446.

34. Londono NC, CasasForero N, Garzon Mendez AF, Dalí Aleixandra Rojas Díaz, Mary Luz Olivares Tenorio, et al. (2026) Tocotrienols: A review from source to therapeutic applications. Food Frontiers 7(2): e70154.

35. Lopresti AL, Smith SJ, Ding L, Li Y, Zhang P (2025) An examination into the effects of tocotrienols (TheraPrimE rice) on cognitive abilities and sleep in healthy adults: A randomised, double-blind, placebo-controlled trial. Front Nutr 12: 1621516.

36. Mathew AM, Bhuvanendran S, Nair RS, Radhakrishnan AK (2023) Exploring the anti-inflammatory activities, mechanism of action and prospective drug delivery systems of tocotrienol to target neurodegenerative diseases. F1000Res 12: 338.

37. Mielke MM, Fowler NR (2024) Alzheimer disease blood biomarkers: Considerations for population-level use. Nat Rev Neurol 20: 495-504.

38. Miller TM, Cudkowicz ME, Genge A, Pamela J Shaw, Gen Sobue, et al. (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387(12): 1099-1110.

39. Mohamad NV (2023) Strategies to enhance the solubility and bioavailability of tocotrienols using self-emulsifying drug delivery system. Pharmaceuticals 16(10): 1403.

40. Morris HR, Spillantini MG, Sue CM, Williams Gray CH (2024) The pathogenesis of Parkinson's disease. Lancet 403(10423): 293-304.

41. Nolan JM, Power R, Howard AN, Paula Bergin, Warren Roche, et al. (2022) Supplementation with carotenoids, omega-3 fatty acids, and vitamin E has a positive effect on the symptoms and progression of Alzheimer's disease. J Alzheimer's Dis 90(1): 233-249.

42. Ooi AG, Yuen KH, Chu CC, Wong JW (2026) Oral delivery of tocotrienols: Addressing pharmacokinetic challenges with formulation-based strategies. Lipids online ahead of print.

43. Ou M, Ying Jiang, Yingying Ji, Qin Zhou, Zhiqiang Du, et al. (2022) Role and mechanism of ferroptosis in neurological diseases. Mol Metab 61: 101502.

44. Razali RA, Wan Ngah WZ, Makpol S, Yanagisawa D, Kato T, et al. (2025) Shifting perspectives on the role of tocotrienol vs. tocopherol in brain health: A scoping review. Int J Mol Sci 26(13): 6339.

45. Sadikan MZ, Abdul Nasir NA, Agarwal R, Mohd Ismail N (2020) Protective effect of palm oil-derived tocotrienol-rich fraction against retinal neurodegenerative changes in rats with streptozotocin-induced diabetic retinopathy. Biomolecules 10(4): 556.

46. Sharif M, Khan DA, Farhat K, Noor M, Khan MA, et al. (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: A systematic review. J Pak Med Assoc 73(3): 603-610.

47. Siderowf A, Concha Marambio L, Lafontant D, Carly M Farris , Yihua Ma, E et al. (2023) Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: A cross-sectional study. The Lancet Neurology 22(5): 407-417.

48. Sims JR, Zimmer JA, Evans CD, Ming Lu, Paul Ardayfio, et al. (2023) Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6): 512-527.

49. Simuni T, Chahine LM, Poston K, Michael Brumm, Teresa Buracchio, et al. (2024) A biological definition of neuronal α-synuclein disease: Towards an integrated staging system for research. Lancet Neurol 23(2): 178-190.

50. Tan JY, Retinasamy T, Lee VLL, Radhakrishnan AK, Yeong KY (2026) Exploring the role of tocotrienol-rich fraction (TRF) in ameliorating neuroinflammation. Inflammopharmacology 34: 4117-4130.

51. Tan SW, Ali DABI, Khazaai H, Wong JW, Vidyadaran S (2020) Cellular uptake and anti-inflammatory effects of palm oil-derived delta (δ)-tocotrienol in microglia. Cellular Immunology 357: 104200.

52. Van Dyck C, Swanson CJ, Aisen P, Randall J Bateman, Christopher Chen, et al. (2023) Lecanemab in early Alzheimer's disease. N Engl J Med 388(1): 9-21.

53. Weiner HL (2025) Immune mechanisms and shared immune targets in neurodegenerative diseases. Nat Rev Neurol 21(2): 67-85.

54. Wu D, Chen Q, Chen X, Han F, Chen Z, et al. (2023) The blood–brain barrier: Structure, regulation and drug delivery. Signal Transduct Target Ther 8(1): 217.

55. Xiang Y, Song X, Long D (2024) Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases. Arch Toxicol 98: 579-615

56. Yunita E, Nasaruddin ML, Ramli NZ, Yahaya MF, Damanhuri HA (2025) Scoping review: The role of tocotrienol-rich fraction as a potent neuroprotective agent. Int J Mol Sci 26(16): 7691.